Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 7
Submit an article Journal homepage
3,615
Views
7
CrossRef citations to date
0
Altmetric
Letters to Editor

Momelotinib reduces transfusion requirements in patients with myelofibrosis

Ruben Mesaa Mays Cancer Center, UT Health San Antonio Cancer Center, San Antonio, TX, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5880-7972View further author information
ORCID Icon,
Stephen T. Ohb Department of Medicine, Washington University School of Medicine, St. Louis, MO, USAView further author information
,
Aaron T. Gerdsc Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USAView further author information
,
Vikas Guptad Department of Medicine, Princess Margaret Cancer Centre, Toronto, ON, CanadaView further author information
,
John Catalanoe Haematology Department, Monash University & Frankston Hospital, Frankston, AustraliaView further author information
,
Francisco Cervantesf Hematology Department, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, SpainView further author information
,
Timothy Devosg Department of Hematology, University Hospitals Leuven and Department of Microbiology and Immunology, Laboratory of Molecular Immunology (Rega Institute), KU Leuven, Leuven, BelgiumView further author information
,
Marek Hush Hematooncology Department, Medical University of Lublin, Lublin, PolandView further author information
,
Jean-Jacques Kiladjiani Université de Paris, AP-HP, Hôpital Saint-Louis, Centre d’Investigations Cliniques, INSERM, Paris, FranceView further author information
,
Ewa Lech-Marandaj Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, PolandView further author information
,
Donal McLornank Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UKView further author information
,
Jeanne Palmerl Division of Hematology and Medical Oncology, Mayo Clinic Hospital, Phoenix, AZ, USAView further author information
,
Uwe Platzbeckerm Department of Hematology, Cellular Therapy and Hemostaseology, Leipzig University Hospital, Leipzig, GermanyView further author information
,
Jacek Trelińskin Department of Hematology, Medical University of Lodz, Lodz, PolandView further author information
,
Kazuya Shimodao Department of Internal Medicine, University of Miyazaki, Miyazaki, JapanView further author information
,
Rafe Donahuep Biometrics, Sierra Oncology Inc, San Mateo, CA, USAView further author information
,
Koenraad D’Hollanderq Biostatistics, International Drug Development Institute, Louvain-la-Neuve, BelgiumView further author information
,
Mark Kowalskir Research and Early Development, Sierra Oncology Inc, San Mateo, CA, USAView further author information
&
Srdan Verstovseks Leukemia Department, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
 show all
Pages 1718-1722 | Received 30 Nov 2021, Accepted 05 Feb 2022, Published online: 07 Mar 2022

References

  • Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the Mayo clinic experience. Mayo Clin Proc. 2012;87(1):25–33.
  • Elena C, Passamonti F, Rumi E, et al. Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. Haematologica. 2011;96(1):167–170.
  • Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (international working group for myeloproliferative neoplasms research and treatment). Blood. 2010;115(9):1703–1708.
  • Nicolosi M, Mudireddy M, Lasho TL, et al. Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. Leukemia. 2018;32(5):1254–1258.
  • Shander A, Cappellini MD, Goodnough LT. Iron overload and toxicity: the hidden risk of multiple blood transfusions. Vox Sang. 2009;97(3):185–197.
  • Bartoszko J, Panzarella T, Lau A, et al. Effect of red blood cell transfusion dependence on the natural history of myeloproliferative neoplasm-associated myelofibrosis. Clin Lymphoma Myeloma Leuk. 2015;15(11):e151–e156.
  • Naymagon L, Mascarenhas J. Myelofibrosis-related anemia: current and emerging therapeutic strategies. Hemasphere. 2017;1(1):e1.
  • Cervantes F, Correa JG, Hernandez-Boluda JC. Alleviating anemia and thrombocytopenia in myelofibrosis patients. Expert Rev Hematol. 2016;9(5):489–496.
  • Hernandez-Boluda JC, Correa JG, Garcia-Delgado R, et al. Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis. Eur J Haematol. 2017;98(4):407–414.
  • Luo X, Xu Z, Li B, et al. Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response. Blood Cancer J. 2018;8(1):9.
  • Mesa RA, Kiladjian JJ, Catalano JV, et al. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-naïve patients with myelofibrosis. J Clin Oncol. 2017;35(34):3844–3850.
  • Harrison CN, Vannucchi AM, Platzbecker U, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2018;5(2):e73–e81.
  • Asshoff M, Petzer V, Warr MR, et al. Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood. 2017;129(13):1823–1830.
  • Oh ST, Talpaz M, Gerds AT, et al. Hepcidin suppression by momelotinib is associated with increased iron availability and erythropoiesis in transfusion-dependent myelofibrosis patients. Blood. 2018;132(Supplement 1):4282–4282.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.